CIRCCa - Cediranib in Recurrent Cervical Cancer

• Research type

  Research Study

• Full title

  CIRCCa (Cediranib In Recurrent Cervical Cancer) A Randomised Double Blind Phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer

• IRAS ID

  36590

• Contact name

  R Paul Symonds

• Sponsor organisation

  NHS Greater Glasgow and Clyde

• Eudract number

  2009-011542-25

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• Research summary

  There is currently no satisfactory treatment for recurrent cervical cancer following chemoradiotherapy. Platinum based combinations are currently indicated as the standard of care and the balance between clinical benefit and toxicity is important to evaluate in each case. The combination of paclitaxel and carboplatin is familar to gynaecological, medical and clinical oncologists and it forms the control arm in this study. This trial will test this combination plus a new drug called cediranib in patients with metastatic/recurrent cervical cancer. The aim of the trial is to increase progression free survival.

• REC name

  East Midlands - Leicester Central Research Ethics Committee

• REC reference

  09/H0406/120

• Date of REC Opinion

  7 Jan 2010

• REC opinion

  Further Information Favourable Opinion